---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-018425"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:48:01.620112+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q1 net loss $100M on $78.6M impairment; Adj. EBITDA $17M beats expectations

## Summary
- Net sales $119.1M (+1.5% YoY); net loss from cont. ops. $100.0M vs $14.4M loss prior year.
- Adjusted EBITDA $17.0M vs $7.2M prior year, exceeding expectations; non-GAAP operating income $13.5M vs $1.9M.
- Non-cash $78.6M impairment write-down on Wound Business now classified as held for sale.
- Signed purchase agreement to divest Wound Business (annual rev ~$40M, Adj. EBITDA ~$5M) on May 10, 2023.
- Cash $47.1M, debt $445.6M; FY 2023 Adj. EBITDA guidance at least $68M excluding Wound Business.

## SEC filing metadata
- accession: 0001628280-23-018425
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828023018425/0001628280-23-018425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828023018425/bvs-20230516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-018425
- JSON: https://secwatch.observer/filing/0001628280-23-018425.json
- Plain text: https://secwatch.observer/filing/0001628280-23-018425.txt

## Key facts
- Earnings Releases
  Bioventus Inc. reported three months ended April 1, 2023 results: revenue $119.1 million, net income $100.0 million, EPS $1.28. Guidance reaffirmed.
  - Period: three months ended April 1, 2023
  - Revenue: $119.1 million
  - Net income: $100.0 million
  - EPS: $1.28
  - Guidance: reaffirmed
  - Result: reported results
  source text: Company"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023. Q1 Financial Summary: • Net Sales of $119.1 million, up $1.8 million, or 1.5%, year-over-year as reported (1.9% constant currency*) • Net Loss from continuing operations of $100.0 million, compared to Net Loss from continuing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828023018425/0001628280-23-018425-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.